Menarini’s EMERALD study of ORSERDU in breast cancer shows promising results
The Menarini Group and its subsidiary, Stemline Therapeutics, Inc., have made a significant stride in breast cancer treatment with new findings from the pivotal EMERALD ... Read More
Menarini’s ORSERDU gets CHMP positive opinion in advanced breast cancer
The Menarini Group and its subsidiary, Stemline Therapeutics Inc., have received a favorable opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for ... Read More
FDA approves Guardant360 CDx assay as companion diagnostic for Menarini’s ORSERDU for metastatic breast cancer
Guardant Health, an oncology company, has secured the approval of the US Food and Drug Administration (FDA) for the company’s Guardant360 CDx liquid biopsy assay ... Read More